Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. announced an increase in its at-the-market (ATM) offering capacity. The company amended its Sales Agreement with Guggenheim Securities, LLC to raise the aggregate offering price for its common stock to up to $150,000,000, an increase of $50,000,000. This capital raise is facilitated through an ATM offering, with a corresponding Shelf Registration Statement on Form S-3 filed with the SEC.

Unicycive Therapeutics announced its financial results for the first quarter ended March 31, 2026, and provided a business update. The FDA review of its oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a PDUFA target action date of June 29, 2026. The company is also continuing commercial readiness activities for the potential launch of OLC. For Q1 2026, Unicycive reported a net comprehensive loss of $(12.8) million, or $(0.54) per share, primarily due to an increase in the fair value of its warrant liability. As of May 11, 2026, the company held $57.1 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2027.

Unicycive Therapeutics announced that the FDA review of its oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026. The company is continuing commercial readiness activities for a potential launch. For the first quarter ended March 31, 2026, Unicycive reported a net comprehensive loss of $(12.8) million, or $(0.54) per share, compared to a net income of $0.5 million, or $0.04 per share, in the prior year period. As of May 11, 2026, cash, cash equivalents, and marketable securities totaled $57.1 million, expected to fund operations into 2027.

Unicycive Therapeutics reported a net loss of $(12.8) million for the three months ended March 31, 2026, a significant decline from a net income of $0.6 million in the prior year period. The company's cash and cash equivalents increased to $37.4 million, primarily driven by $19.6 million in net proceeds from a secondary public offering. Operating expenses increased, and the change in fair value of warrant liability negatively impacted results.

Unicycive Therapeutics, Inc. will hold its Annual Meeting of Stockholders on June 19, 2026, to elect three directors and ratify the appointment of Grassi & Co. CPAs, P.C. as its independent registered public accounting firm for fiscal year ending December 31, 2026. The company also announced the resignation of independent director Gaurav Aggarwal on April 6, 2026, and plans to appoint new independent directors to its Board and committees by October 3, 2026, to comply with Nasdaq rules.

Gaurav Aggarwal, a director of Unicycive Therapeutics, Inc., resigned from the Board of Directors on April 6, 2026. The resignation was not due to any disagreement with the company's operations, policies, or practices. This change in board composition could be of interest to investors monitoring the company's leadership and governance.